- AbbVie’s Risankizumab for Crohn’s disease receives positive opinion from UK MHRA
- Chinese COVID-19 vaccines are not so effective against COVID-19 and not suitable as booster shot.
- Shanghai COVID outbreaking: over 500K people infected and 87 deaths
- More than 70% of COVID-19 patients still have sequelae after one year
- First cases of mink-to-human transmission of COVID-19 in United States
- Biogen withdraws marketing application of Alzheimer’s drug Aduhelm from EU
China adenovirus vector COVD-19 vaccine Date released 74.8% effective
China adenovirus vector COVD-19 vaccine Date released 74.8% effective. Chen Wei’s team announced the latest data on the adenovirus vector COVID-19 vaccine, and the overall protection effect of single-shot vaccination was 74.8%.
The latest data on the adenovirus vector vaccine Ad5-nCoV jointly developed by the Chen Wei team, an academician of the Chinese Academy of Engineering and a researcher at the Academy of Military Medical Research of the Academy of Military Sciences, and Cansino Biosciences has been released recently. The results of the interim analysis of the Phase III clinical trial of Ad5-nCoV in Pakistan showed that the protective effect of single-shot vaccination against severe new coronavirus pneumonia was 100%, and the overall protective effect was 74.8%.
Pakistani health officials announced the interim data of the country’s Ad5-nCoV Phase III clinical trial on February 8. 28 days after the single injection, the vaccine’s protective efficacy against severe new coronavirus pneumonia was 100%, and the overall protective efficacy was 74.8%. There was no serious adverse reaction related to the vaccine.
Currently, Ad5-nCoV is undergoing phase III clinical trials in countries including Mexico, Russia, Pakistan, Argentina and Chile. On February 1, Cansino Biologics issued an announcement stating that the Phase III clinical trial of Ad5-nCoV has completed inoculation of more than 40,000 subjects in 78 clinical research centers in 5 countries. According to global test data, 28 days after a single injection, the vaccine has a protective effect of 90.98% against severe new coronavirus pneumonia and an overall protective effect of 65.7%.
Vaccines are the key to epidemic prevention and control. Many countries around the world are racing against time to develop COVID-19 vaccines. China has laid out five technical routes to advance simultaneously, and adenovirus vector vaccine is one of them. The principle is to use the modified non-pathogenic adenovirus as a carrier, and implant the extracted virus antigen gene into the adenovirus, so that the adenovirus can express the virus antigen without causing virus toxicity. After the adenovirus vector vaccine is injected into the human body, the immune system will recognize the viral antigen and activate the body’s immune response to gain immunity.
The reporter combed and found that as early as March 16 last year, the adenovirus vector COVID-19 vaccine developed by Chen Wei’s team was approved to start clinical trials. It was China’s first COVID-19 vaccine to enter clinical trials; on April 12, phase II clinical trials were launched. The trial is the world’s first COVID-19 vaccine to enter Phase II clinical research. The data of the two-phase clinical trials were published in the internationally renowned medical journal “The Lancet”. The results showed that the vaccine is safe, well tolerated, and has no serious adverse reactions.
Ad5-nCoV is a rare single shot vaccine. It is understood that the world’s current research and development using the same technical route as the Ad5-nCoV vaccine also include the AZD1222 vaccine jointly developed by Oxford and AstraZeneca, the Johnson & Johnson Ad26.COV2.S vaccine and the Russian satellite V vaccine, of which only the Ad5-nCoV vaccine The vaccine with Johnson & Johnson is a single shot vaccine. However, the Phase III clinical trial of Johnson & Johnson vaccine only announced that the total effective rate for moderate to severe cases reached 66%, and did not announce the overall protective efficacy including mild cases.
Another feature of Ad5-nCoV is that it only needs to be stored at 2 to 8 degrees Celsius, and its transportation and distribution also have greater advantages than many vaccines. Coupled with the simple procedure for single-shot vaccination, Ad5-nCoV can achieve large-scale and rapid population vaccination in the future, which is of great significance to the overall epidemic prevention strategy of society.
(source:internet, reference only)